NCT04465890View on ClinicalTrials.gov

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2024

Conditions
Chronic Hepatitis b
Interventions
DRUG

ASC22

200mg/1ml/1bottle

DRUG

sodium chloride

90mg/10ml/1 bottle

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Peking University First Hospital

OTHER

collaborator

Beijing Clinical Service Center

OTHER

lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY